Neuroendocrine Cancer Research at UPMC
UPMC and its academic partner, the University of Pittsburgh, are world-renowned for providing leading-edge research designed to find the latest advances in cancer prevention, detection, diagnosis, and treatment.
A clinical trial is a way for physicians to test a new treatment for its safety and effectiveness. Participants are typically patients who have the disease. Participants must be informed of the possible risks and benefits associated with the clinical trial, and are required to follow all treatment protocol.
Neuroendocrine Cancer Clinical Trials at UPMC
Some of our current research and clinical trial activities in the field of neuroendocrine cancer treatment include:
Pathfinder NIH Trial – This novel investigation provides instant feedback to surgeons and helps them make decisions during liver surgery for neuroendocrine cancer.
Tissue/Serum/Urine Bank – This effort stores samples of tissue, serum, and urine from neuroendocrine cancer patients who are seen in the clinic or in the operating room. These samples are catalogued and stored for molecular analysis, and for collaboration with other research initiatives throughout UPMC and the University of Pittsburgh School of Medicine
Regional chemoembolization – A therapy for inoperable liver tumors, chemoembolization remains an important part the Neuroendocrine Cancer Center's treatment approach. With over 300 treatments of chemoembolization administered yearly, our center is widely recognized as a leader in the field.
Yttrium 90 (Y90) – This is an evolving therapy for inoperable neuroendocrine tumors. Although the use of Y90 for neuroendocrine cancer is limited, this therapy represents an exciting area for upcoming investigation.
Learn More About Neuroendocrine Cancer Research
To find out more about neuroendocrine cancer research at UPMC, including whether you may qualify to participate in a clinical trial for neuroendocrine cancer treatment, please call our office at 412-692-2001, or visit Pitt's Office of Clinical Research.